In 2010, the first prospective, randomised, multicentre phase III study was published (the ToGA study), in which the efficacy and safety of the monoclonal antibody, Trastuzumab was evaluated in advanced gastric adenocarcinoma and cancer of the gastroesophageal junction overexpressing human epidermoid growth factor receptor 2 (HER2) [8]. Here, ERBB2 is linked to cancer.